Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | GBA1 | P04062 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1745345 | 1.00 | LMNA (0.49) | LMNAMAPK1SMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL1745871 | 0.98 | LMNA (0.52) | LMNAMAPK1SMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL1743382 | 0.98 | LMNA (0.52) | LMNAMAPK1SMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL1745898 | 0.98 | LMNA (0.52) | LMNAMAPK1SMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL1746016 | 0.98 | LMNA (0.52) | LMNAMAPK1SMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL1743153 | 0.97 | LMNA (0.48) | LMNAMAPK1SMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL1746276 | 0.97 | LMNA (0.48) | LMNAMAPK1SMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL9994885 | 0.87 | RAB9A (0.52) | LMNASMN1; SMN2NPC1ALDH1A1HPGD | |
| Cyclopentane SCHEMBL9994808 | 0.87 | RAB9A (0.52) | LMNASMN1; SMN2NPC1ALDH1A1HPGD | |
| SCHEMBL9994799 | 0.87 | RAB9A (0.52) | LMNASMN1; SMN2NPC1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2386556-B1 | Benzothiazole cyclobutyl amine derivatives and their use as histamine-3 receptors ligands | ABBVIE INC (US) | 2013-10-23 | — | — | EP | claimed |
| EP-1926729-B1 | BENZOTHIAZOLE CYCLOBUTYL AMINE DERIVATIVES AND THEIR USE AS HISTAMINE-3 RECEPTORS LIGANDS | ABBOTT LAB (US) | 2011-12-21 | — | — | EP | claimed |
| EP-2386556-A1 | Benzothiazole cyclobutyl amine derivatives and their use as histamine-3 receptors ligands | Abbott Laboratories (US) | 2011-11-16 | — | — | EP | claimed |
| US-20110254413-A1 | CASING OF ELECTRONIC DEVICE AND MANUFACTURING METHOD THEREOF | ASUSTEK COMPUTER INC. (TW) | 2011-10-20 | — | — | US | claimed |
| US-7576110-B2 | Benzothiazole cyclobutyl amine derivatives | ABBOTT LABORATORIES (US) | 2009-08-18 | — | — | US | claimed |
| EP-1926729-A1 | BENZOTHIAZOLE CYCLOBUTYL AMINE DERIVATIVES AND THEIR USE AS HISTAMINE-3 RECEPTORS LIGANDS | ABBOTT LABORATORIES (US) | 2008-06-04 | — | — | EP | claimed |
| WO-2007038074-A1 | BENZOTHIAZOLE CYCLOBUTYL AMINE DERIVATIVES AND THEIR USE AS HISTAMINE-3 RECEPTORS LIGANDS | ABBOTT LABORATORIES (US) | 2007-04-05 | — | — | WO | claimed |
| US-20070066588-A1 | Benzothiazole cyclobutyl amine derivatives | ABBVIE INC. | 2007-03-22 | — | — | US | claimed |
| US-8592467-B2 | Benzothiazole cyclobutyl amine derivatives | ABBVIE INC. (US) | 2013-11-26 | — | — | US | disclosed |
| EP-2386556-B1 | Benzothiazole cyclobutyl amine derivatives and their use as histamine-3 receptors ligands | ABBVIE INC (US) | 2013-10-23 | — | — | EP | disclosed |
| EP-1926729-B1 | BENZOTHIAZOLE CYCLOBUTYL AMINE DERIVATIVES AND THEIR USE AS HISTAMINE-3 RECEPTORS LIGANDS | ABBOTT LAB (US) | 2011-12-21 | — | — | EP | disclosed |
| EP-2386556-A1 | Benzothiazole cyclobutyl amine derivatives and their use as histamine-3 receptors ligands | Abbott Laboratories (US) | 2011-11-16 | — | — | EP | disclosed |
| US-20110254413-A1 | CASING OF ELECTRONIC DEVICE AND MANUFACTURING METHOD THEREOF | ASUSTEK COMPUTER INC. (TW) | 2011-10-20 | — | — | US | disclosed |
| US-20090326222-A1 | BENZOTHIAZOLE CYCLOBUTYL AMINE DERIVATIVES | ABBOTT LABORATORIES (US) | 2009-12-31 | — | — | US | disclosed |
| US-7576110-B2 | Benzothiazole cyclobutyl amine derivatives | ABBOTT LABORATORIES (US) | 2009-08-18 | — | — | US | disclosed |
| EP-1926729-A1 | BENZOTHIAZOLE CYCLOBUTYL AMINE DERIVATIVES AND THEIR USE AS HISTAMINE-3 RECEPTORS LIGANDS | ABBOTT LABORATORIES (US) | 2008-06-04 | — | — | EP | disclosed |
| WO-2007038074-A1 | BENZOTHIAZOLE CYCLOBUTYL AMINE DERIVATIVES AND THEIR USE AS HISTAMINE-3 RECEPTORS LIGANDS | ABBOTT LABORATORIES (US) | 2007-04-05 | — | — | WO | disclosed |
| US-20070066588-A1 | Benzothiazole cyclobutyl amine derivatives | ABBVIE INC. | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326222-A1 | BENZOTHIAZOLE CYCLOBUTYL AMINE DERIVATIVES | HRH2, HRH4, HRH1 | LMNA 4292/4885MAPK1 2499/4885SMN1; SMN2 3835/4885 |
| US-20070066588-A1 | Benzothiazole cyclobutyl amine derivatives | HRH2, HRH4, HRH1 | LMNA 4292/4885MAPK1 2499/4885SMN1; SMN2 3835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.